Jianming Lu
- Sensory Systems top 2%
- Oncology top 10%
- Chemokine receptors and signaling 4
- CAR-T cell therapy research 2
- Infectious Diseases top 5%
- SARS-CoV-2 and COVID-19 Research 3
- Viral gastroenteritis research and epidemiology 2
- Molecular Biology top 10%
- Angiogenesis and VEGF in Cancer 5
- Viral Infectious Diseases and Gene Expression in Insects 2
-
- Cancer, Hypoxia, and Metabolism 2
-
- Virus-based gene therapy research 2
Jianming Lu
26 papers receiving 1.6k citations
Hit Papers
Peers
Comparison fields: 5 of 101
- Sensory Systems 153
- Oncology 399
- Infectious Diseases 267
- Molecular Biology 898
- Immunology 211
Countries citing papers authored by Jianming Lu
This map shows the geographic impact of Jianming Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianming Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianming Lu more than expected).
Fields of papers citing papers by Jianming Lu
This network shows the impact of papers produced by Jianming Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianming Lu. The network helps show where Jianming Lu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jianming Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 3 | |
| 3 | 2022 | 4 | |
| 4 | Structural impact on SARS-CoV-2 spike protein by D614G substitutionbreakdown → | 2021 | 270 |
| 5 | 2021 | 11 | |
| 6 | 2015 | 23 | |
| 7 | 2015 | 15 | |
| 8 | 2015 | 1 | |
| 9 | 2013 | 25 | |
| 10 | 2012 | 100 | |
| 11 | 2012 | 39 | |
| 12 | 2012 | 57 | |
| 13 | 2010 | 51 | |
| 14 | 2009 | 90 | |
| 15 | The Src family kinase inhibitor, dasatinib, inhibits angiogenesis in vitro and in vivo | 2008 | 3 |
| 16 | 2002 | 314 | |
| 17 | 2001 | 2 | |
| 18 | 1999 | 328 | |
| 19 | 1998 | 7 | |
| 20 | 1992 | 5 |
About Jianming Lu
Jianming Lu is a scholar working on Oncology, Toxicology and Hematology, having authored 27 papers that have together received 1.6k indexed citations. Recurring topics across this work include Angiogenesis and VEGF in Cancer (5 papers), Chemokine receptors and signaling (4 papers), SARS-CoV-2 and COVID-19 Research (3 papers), Viral gastroenteritis research and epidemiology (2 papers), Cancer, Hypoxia, and Metabolism (2 papers), Virus-based gene therapy research (2 papers), CAR-T cell therapy research (2 papers) and Viral Infectious Diseases and Gene Expression in Insects (2 papers). The work is most often cited by research in Sensory Systems (153 citations), Oncology (399 citations) and Infectious Diseases (267 citations). Jianming Lu has collaborated with scholars based in United States, Japan and China. Frequent co-authors include Eric Delpire, Kerstin Piechotta, Roger England, Tina Thorne, Eileen L. Heinrich, Joseph Kim, Keqiang Zhang, Wendy Lee, Wei Wen and Jun Zhang. Their work appears in journals such as Science, Journal of the American Chemical Society and Journal of Biological Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.